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At Jefferson, that time is now.

On the Cover:
Christine Arenson, MD, Associate Professor and Director, Division of Geriatric Medicine, Department of Family and Community
Medicine, and Molly Rose, FNP, PhD, Professor, School of Nursing (not pictured), have been instrumental in establishing the
Jefferson InterProfessional Education Center. One of only a few nationwide, the Center focuses on improving patient care
through facilitation, implementation and evaluation of a team-based education curriculum for Jefferson students.

A message from Robert L. Barchi
and Brian G. Harrison
Thomas Jefferson University has a legacy of being at the forefront of healthcare education that
began in 1824 with our medical school founder, George McClellan, MD. He believed the best
approach to education was supervised student participation in patient care. At the time, this was
considered revolutionary.
Nearly two centuries later, we’re still redefining healthcare education and research. We can – and do –
provide an environment where faculty, students and researchers learn and effect changes that make
a difference not only in the lives of patients, but for the good of society.
As Jefferson looks ahead, we see opportunity to do even more. We recently established the Jefferson
School of Health Policy and Population Health, founded on the belief that providers must understand
global healthcare to improve the health of populations here. In 2009, students will learn about the
complexities of population health, how to set health policy standards, and manage healthcare quality,
safety and chronic care.
Following our strategic plan that identified the need for more facilities to educate pharmacists, we
opened the School of Pharmacy. Our first class of 75 was chosen from more than 900 applicants.
Students now participate in a program that leverages the benefits of an academic organization offering
a full complement of healthcare education.
To address the growing need for multidisciplinary patient care, Jefferson continues to develop
curricula that foster a team approach to treatment. We lead the way with innovative instruction
through the Jefferson InterProfessional Education Center. Jefferson Health Mentors immerses all students
in a two-year program working with the chronically ill, while our Clinical Skills and Simulation
Center uses state-of-the-art technology to create realistic medical training simulations for students.
Jefferson’s commitment to advancing research that translates to better quality of life is also a hallmark
of our institution. Recent exciting discoveries in cardiology, cancer and neuroscience promise to
change the course of treatment as well as the manner in which certain diseases are viewed.
From education, to patient care and research, we know that the combined intellect of the healthcare
leaders of tomorrow will translate to exceptional treatment and breakthrough discoveries. At Jefferson,
we’re on the cusp of transforming the way patient care is delivered.

Robert L. Barchi, MD, PhD

Brian G. Harrison

President

Chair, Board of Trustees

Education
Learning and Healing as a Team
“Teaching students to
see and understand
the complexities of
a patient’s entire
health history – and
not just treat the
acute episode as a
solitary event – is an
important building
block to providing
comprehensive
care.”
Michael Vergare, MD
Interim Dean

Providing care to patients with chronic conditions requires a coordinated
approach – with a team of healthcare professionals making critical decisions
together. Recognizing that patients often need care from many different
specialists, Thomas Jefferson University has created the Jefferson InterProfessional Education Center (JCIPE). Its goal is to develop a practice
model promoting synergies among healthcare providers that can be applied
in the real world as students begin their medical careers. This model will
transform healthcare delivery.
One of only a few centers nationwide, JCIPE is co-directed by Christine
Arenson, MD, Director, Division of Geriatric Medicine, Department of
Family and Community Medicine, and Molly Rose, FNP, PhD, Professor
in the School of Nursing. The Center focuses on improving patient care
through facilitation, implementation and evaluation of a team-based
curriculum. Students in medicine, nursing, physical and occupational
therapy, family and couple therapy and pharmacy learn together in an
environment that fosters interaction and respect for each other’s disciplines
and specialized skills.
An important component of this team education is a two-year program,
called Jefferson Health Mentors, where multidisciplinary teams of students
are mentored by patients with chronic illnesses. Together, students from
JMC and the schools of Nursing, Health Professions and Pharmacy work

to gain a comprehensive view of the patient’s treatment challenges. The
shared learning contributes to a greater appreciation of the value this
integrated treatment approach has to the patient.
The real-life patient experience students receive is enhanced by the
high-tech training delivered through the university’s Clinical Skills and
Simulation Center. Here, teams use simulated patient scenarios – from acute
episodes such as heart attacks, to labor and delivery – to experience medical
events that are extremely realistic.
Co-directed by Dale Berg, MD, and Kate Berg, MD, the Center provides
replicas of operating and emergency rooms and ICUs and hospital rooms.
Students use simulation manikins and interact with patient actors to enhance
the realism of medical events. The faculty then translates what’s happening
in these labs to what is likely to occur at the patient’s bedside. These
scenarios offer students an opportunity to learn and repeat procedures – even
for rarely experienced events – so that when confronted with real patient
events, they are already highly experienced.
When interdisciplinary education is combined with high-tech simulations
and patient mentoring, the management of chronic illness and acute episodes
becomes very real for Jefferson students. This approach to medical care
offers our future healthcare professionals an education unmatched in the
region and unsurpassed in the nation.

Jefferson Medical College

Accomplishments
• Jefferson and the Foundation for Advancement

• The Department of Family and Community

has experienced a 130% jump since 2004; our

of alumnus Dr. Robert and Dorothy Rector to be

Medicine received a three-year grant from the

will jointly support projects in resource-limited

BSN degree program enrollment increased by

used for the university’s educational mission

Bureau of Health Professions. Jefferson will

countries that focus on faculty development,

nearly 50%.

and to support our Clinical Skills Center where

expand its rural Physician Shortage Program to

interdisciplinary learning is the standard.

Delaware, where students will be committed

medical education.

Thomas Jefferson University

• Jefferson received $7.5 million from the estate

of International Medical Education and Research

continuing medical education and research in
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• Enrollment in Jefferson’s MSN degree program

to practicing medicine after they graduate.

At the Dr. and Mrs. Robert D. Rector Clinical Skills Center multidisciplinary student teams work together in state-of-the-art simulation labs to perform clinical procedures such
as vital signs, single-lead electrocardiogram, deﬁbrillation, intubation, vein puncture and urinary catheterization. Led by the Center’s Co-Directors, Dale Berg, MD, and Katherine
Berg, MD, (pictured here) students are introduced to real-world scenarios, allowing them to practice and perfect their techniques in a safe, hands-on environment.

Education
“The School of
Pharmacy develops
programs that
redefine the
pharmacist’s
role in healthcare
and complement
the university’s
curricula which are
designed to support
collaborative
healthcare teams.”

A Prescription for Change
Inspiring students to think beyond the traditional boundaries of pharmacy
and their roles as pharmacists are important goals of the School of
Pharmacy, opened in September of 2008.
As part of the Jefferson College of Health Professions, the School of
Pharmacy leverages the benefits of being part of an integrated academic
organization with a full complement of healthcare education. Students are
immersed in a system that fosters interprofessional collaboration among
many healthcare disciplines and allows them to train alongside medical,
nursing, physical and occupational therapy students.
Rebecca Finley, PharmD, MS, and Dean of the Jefferson School of
Pharmacy, has assembled a faculty whose shared enthusiasm for making
real-life connections is key to teaching pharmacy students the important

Rebecca Finley, PharmD, MS
Dean, Jefferson School of Pharmacy

Accomplishments
• The Department of Radiologic Sciences received

• The Center for Applied Research on Aging and

accreditation of its MRI and Nuclear Medicine

Health received the Rosalynn Carter Institute

programs by their Joint Review Committees.

for Caregiving/Johnson & Johnson Award. The

The programs were recognized for outstanding

grant supports clinician training to assess the

preparation of professionals in the ﬁeld.

needs of caregivers and better manage care for

Jefferson is among only a few in the Northeast to

dementia patients.

hold this accreditation.
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and evolving role they will play in delivering healthcare. Work partnerships
with retail and hospital pharmacies give students the opportunity to
take classroom lessons out into the community from the very first week
of school.
The first class of 75 students, chosen from a pool of more than 900
applicants, represents individuals from 26 states – a testament to Jefferson’s
strategic plan that uncovered the pressing need for more facilities to educate
the pharmacists of tomorrow.

For Rebecca Finley, PharmD, MS, and Dean, Jefferson School of Pharmacy, one measure of success is the
numbers. More than 900 applicants vied for 75 slots in the School of Pharmacy, which opened its doors to the
first class this past September.

Health Matters
Complexities in managing population health and its corresponding policies
have created a demand for leadership that is prepared to take on new roles.
Many challenges, such as aging populations, chronic diseases and disparities
in treatment access, have taxed the healthcare system. There is an imminent
need to improve the system so it can support research, test interventions,
set standards and deliver care for the greater good.
Jefferson is committed to redefining healthcare education and also
has broadened its offerings to keep pace with the changing landscape by
establishing the School of Health Policy and Population Health (JSHPPH).
Under the direction of David B. Nash, MD, MBA, and with support from
Richard Wender, MD, JSHPPH will take the public health programs already
offered at the Jefferson College of Graduate Studies to an even higher level
– offering new certificate and master’s degree programs in health policy,
healthcare quality and safety and chronic care management.
The health of everyone in our society matters. Thomas Jefferson University
is uniquely positioned through the JSHPPH to educate the healthcare
leaders of tomorrow who will play critical roles in reducing inequalities
in health between population groups.

“Students will learn
about the economic,
social, environmental
and biological factors
that influence the
health of populations.
Then, they can be
part of the solution,
by developing policy
approaches that
improve health
outcomes among
all groups.”

Accomplishments
David B. Nash, MD, MBA
• The Jefferson School of Health Policy and

• Thomas Jefferson University and Widener School

Population Health received a grant to develop

of Law now offer two dual degree programs –

the Doris N. Grandon Center for Health

Juris Doctor/Master of Public Health (JD/MPH)

Economics and Outcomes Research. The new

and Master of Jurisprudence/Master of Public

space includes facilities to support important

health (MJ/MPH) – the only programs of their

research in this area.

kind in the Delaware Valley.

Dean, Jefferson School of Health Policy
and Population Health

David B. Nash, MD, MBA, (right) Dean, Jefferson School of Health Policy and Population Health, pictured
here with Richard Wender, MD, Chair of the Department of Family and Community Medicine and of the new
School’s Advisory Committee. Through the School, Drs. Nash, Wender and their teams will prepare leaders to
develop and implement policies and systems focused on improving healthcare for all populations of society.

Thomas Jefferson University
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Research
Stemming the Tide of Cancer
“With $78.2 million
in NCI grants,
we’re supporting
73 cancer-related
studies at the
Kimmel Cancer
Center.”
Richard G. Pestell, MD, PhD,
MBBS, FRACP
Director, Kimmel Cancer Center at
Jefferson, Associate Dean, Cancer
Programs, Jefferson Medical College

After a rigorous, competitive review process by the National Cancer Institute
(NCI), Jefferson’s Kimmel Cancer Center (KCC) has, once again, been
awarded the prestigious title of an NCI-Designated Cancer Center. Since
1995, KCC has been continuously recognized by NCI as a center of scientific
excellence for the treatment of cancer and cancer-related illnesses.
An elite group of sixty cancer centers nationwide are awarded NCI
designation. During the review process, KCC received accolades for its high
level of education, research and clinical care standards, as well as recognition
for its tremendous growth in faculty, grant awards and clinical trials.
Under the leadership of Richard G. Pestell, MD, Director of the Kimmel
Cancer Center, KCC has secured significant, new NCI funding and will
retain this designation through 2013. As part of Jefferson’s strategic plan,
the Center plans to apply for Comprehensive Cancer Center status, which
would place KCC in an even more select group of cancer facilities.
Through the recent establishment of the Jefferson Stem Cell Biology and
Regenerative Medicine Center, Thomas Jefferson University and KCC have
further supported their mission to discover new treatments that will redefine
the future of clinical care. Under the direction of Michael P. Lisanti, MD,
PhD, Professor of Cancer Biology and the Margaret Q. Landenberger

Professor of Breast Cancer Research, researchers are studying the biology,
behavior and medical uses of adult stem cells to treat cancer and other
diseases.
One area of concentration for the Center is to understand the function of
cancer stem cells. Investigators are studying ways to identify and develop
new biomarkers related to cancer stem cells. Their predictive values will lead
to better, targeted therapies for cancer.
Clinical pharmacologist Scott A.Waldman, MD, PhD, Professor and Chair
of Pharmacology and Experimental Therapeutics is leading the way in other
areas of cancer research. Through his research on a vaccine for colorectal
cancer, Dr. Waldman has found a way to immunize mice against the
development of metastatic disease, or the spread of cancer from one part
of the body to another. Immunized first with an intestinal protein called
guanylyl cyclase C (GCC) and then injected with colon cancer cells, the
animals developed 90 percent fewer liver and 75 percent fewer lung
metastases. In the future, immunizing individuals with the protein GCC
could help fight colorectal cancer and other cancers that originate and
metastasize from mucosa.

Accomplishments
• Investigators at Jefferson’s Kimmel Cancer Center

• Neal Flomenberg, MD, was appointed Chair for

• Mathew Thakur, PhD, Professor of Radiology and

• Researcher Marja Nevalainen, MD, PhD, Associate

have found that the gene USP22 can predict which
tumors are likely to be aggressive. The studies,

the Department of Medical Oncology. He is the

Radiation Oncology/Nuclear Medicine has been

Professor of Cancer Biology, and her colleagues

Director of the Hematologic Malignancies and

awarded the 2008 Cassen Prize for outstanding

have shown that by blocking signaling protein

led by Steven McMahon, PhD, Associate Professor

Hematopoietic Stem Cell Transplant programs and

achievements in promoting the development and

Stat3, they can prevent prostate cancer cells from

of Cancer Biology, have shown this gene to be a

Professor of Medical Oncology, Microbiology and

growth of Nuclear Medicine.

spreading. Future studies will examine Stat3 as

potential target for new anti-cancer drugs.

Immunology at Jefferson Medical College.

a target for therapies aimed at keeping prostate
cancer at bay.
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Richard G. Pestell, MD, PhD, MBBS, FRACP, Director, Kimmel Cancer Center at Jefferson, Michael P. Lisanti, MD, PhD, Professor, Department of Cancer Biology and Scott A. Waldman, MD, PhD, Professor
and Chair of Pharmacology and Experimental Therapeutics have more than seven decades of combined expertise in the diagnosis and treatment of various cancers. With their contributions as well as
those from teams of scientists and healthcare providers, Thomas Jefferson University Hospitals is now ranked 28th in the nation for cancer care by U.S.News & World Report.

Research
Getting to the Heart of It
“This record-setting
NIH grant will fund
research across
institutions. We can
pool decades of
knowledge from our
organizations to
study cardiac injury
that leads to heart
failure, and develop
novel therapeutic
strategies to treat a
failing heart.”

The path to scientific discovery starts with a desire for knowledge and
the support of leaders who share a passion for getting to the heart of the
matter – finding answers that will help cure diseases and save lives. Through
a five-year, $11.6 million dollar grant from the National Heart, Lung and
Blood Institute (NHLBI), cardiovascular disease researchers at Jefferson
and other area institutions are on a quest to do just that.
As testimony to its reputation as an exceptional research institution,
Jefferson Medical College has been awarded one of the largest research
grants in the history of the institution. Under the leadership of Walter J.
Koch, PhD, the W.W. Smith Professor of Medicine and the Director of the
Center for Translational Medicine, this multi-center grant is funding four
projects to identify new molecular pathways and target molecules that can
repair a failing heart.
One of these projects is led by Primary Investigator Thomas G. Force, MD,
the James C. Wilson Professor of Medicine. Known for his earlier research
revealing that a certain type of cancer-fighting drug called a tyrosine kinase
inhibitor (TKI) can cause heart failure, Dr. Force has since discovered that

this drug may actually damage heart stem cells and prevent repair. With this
grant Dr. Force will continue to lead a group that will test the tyrosine kinase
inhibitor drugs to better understand how they affect cardiac stem cells.
Another group led by Arthur Feldman, MD, PhD, the Magee Professor
and Chair of Medicine at Jefferson Medical College, will focus on the role
of adenosine receptors in the heart. While much is known about their role
in protecting the heart when it’s deprived of oxygen during a heart attack,
little is known about what part they play in heart failure or in healing the
heart after injury.
Advancing another area of cardiovascular research through a separate
NHLBI grant is Paul F. Bray, MD, the Thomas Drake Martinez Cardeza
Professor of Medicine. He and colleagues from 40 centers nationwide have
found that women with no history of heart disease do not have an elevated
risk of cardiac problems if they receive hormone replacement therapy.
Dr. Bray and his colleagues have found that a simple blood test measuring
cholesterol levels would give physicians a good basis to determine whether
a post-menopausal patient is a candidate for hormone therapy.

Accomplishments
Walter J. Koch, PhD
W.W. Smith Professor of Medicine
and Director of the Center for
Translational Medicine

• A study of 5,000 heart attack patients found that

Thomas Jefferson University

• Scientists have found that the protein S100A1

a partially puriﬁed extract of Chinese red yeast

and Chair of Medicine was selected as Editor-in-

may have protective effects for blood pressure.

rice reduced repeat heart attacks by 45 percent

Chief of the new journal Clinical and Translational

Assistant Professor of Medicine, Patrick Most, MD,

and revascularization and mortality by one-third.

Science. He will work in partnership with Deputy

discovered that by lowering S100A1 in an animal’s

Findings were reported by corresponding author

Editor Scott A. Waldman, MD, PhD, Professor and

blood vessels, blood pressure could be increased.

David M. Capuzzi, MD, PhD, Director of the

Chair of Pharmacology and Experimental

This suggests the protein could be a therapeutic

Cardiovascular Disease Prevention, Myrna Brind

Therapeutics.

target for blood pressure treatment.

Center of Integrative Medicine.
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• Arthur Feldman, MD, PhD, the Magee Professor

With an $11.6 million NIH Program Project Grant, scientists are studying the molecular mechanisms of cardiac injury that lead to heart failure. Funding for the project, led by Principal
Investigator, Walter J. Koch, PhD, Director, Center for Translational Medicine, supports four core areas: administration, surgical, molecular and gene therapy, as well as four main laboratory
facilities. Pictured with Dr. Koch (left) are the leaders of these facilities, Patrick Most, MD, PhD, Erhe Gao, MD, PhD, Andrea Eckhart, PhD, and Joseph Rabinowitz, PhD.

Research
Unlocking the Secrets of Our Nerve Center
“The research
we’re doing in
Multiple Sclerosis
can potentially
change the course
of this devastating
disease, which
affects nearly
half-a-million
Americans.”
A.M. Rostami, MD, PhD
Professor and Chair
Department of Neurology

Professor and Chair of the Department of Neurology, A.M. Rostami,
MD, PhD, and his team have developed models with a Multiple Sclerosislike disease to study their response to the protein interkeukin-27 (IL-27).
Investigators have found that this protein helped to block or reverse
MS symptoms, suggesting that one day it may be an important addition
to current therapy for millions suffering with MS.
This study revealed that IL-27 functions in two important ways: it
suppresses an inflammatory immune response, decreasing the damage to
healthy brain and nerve cells, and it increases the production of an antiinflammatory protein that suppresses the uncontrolled symptoms that many
MS sufferers experience. For Dr. Rostami, these findings provide the
evidence needed to study human blood samples, in the hopes that similar
results will support the successful therapeutic application of IL-27.
In his journey to help patients overcome debilitating migraines, Stephen
D. Silberstein, MD, Professor of Neurology and Director of the Jefferson
Headache Center, is leading two key clinical trials designed to test the
effectiveness of pain relief for both episodic and chronic migraines.
The Headache Center – one of the few academic headache centers in the
country – offers unique, high-level tertiary care.

Dr. Silberstein is currently testing an implantable Occipital Nerve
Stimulator with an external controller that can be adjusted by the patient to
manage headache pain. In a second trial, he presented promising results
demonstrating that magnetic stimulation by an external device held at the
back of the head, can “turn off ” the pain for people with mild to moderate
migraines. For more than 28 million Americans who suffer migraines, Dr.
Silberstein’s research may eventually offer relief to those who don’t respond
to conventional treatments.
A new $3.5 million grant from the National Eye Institute has been
awarded to the Farber Institute for Neurosciences to support important
research in age-related macular degeneration (AMD), the leading cause of
blindness in older persons in the U.S. Under the leadership of Barry W.
Rovner, MD, Professor of Psychiatry and Neurology, and Director of the
Center for Clinical Alzheimer’s Disease Research, the grant will fund
community-based clinical trials aimed at preventing depression and
improving vision function in patients with AMD. The investigations will
test the effectiveness of rehabilitative intervention by an occupational
therapist and a low-vision optometrist to reduce the occurrence of depression
in those with the disease.

Accomplishments
• Jefferson has established a Parkinson’s disease

• Jefferson is one of the busiest neurovascular/

and Movement Disorders Center with the addition

endovascular neurosurgery practices nationwide.

conducted in epilepsy, headache, stroke, Multiple

of two specialists in this area. Within the past

It’s also among the first in the U.S. to explore a

Sclerosis, Neuroimmunology and Neurogenetics.

three years, Neurology has built a specialty clinical

new FDA-approved liquid system treatment for

practice numbering over one thousand patients.

patients with wide-neck brain aneurysms.
If effective, the treatment could be an alternative
for aneurysms not always responsive to
surgical options.
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• More than 70 extensive clinical trials are being

Stephen D. Silberstein, MD, Professor of Neurology and Director, Jefferson Headache Center, uses a Transcranial Doppler
(TCD) to measure levels of nitric oxide and endothelin-1 in migraine patients. Monitoring blood flow through vessels in the
brain during a migraine has yielded important data on what triggers these attacks and why they persist.

Barry W. Rovner, MD, Professor of Psychiatry and Neurology, discusses
neovascular age-related macular degeneration with a patient. Dr. Rovner
received a $3.5 million grant from the National Eye Institute to support
clinical trials aimed at preventing depression and improving vision
function in patients with age-related macular degeneration.

Research
A Center of Strength
“Creating the Vaccine
Center is a natural
progression for us.
With a critical mass
of expertise in
one place and the
infrastructure
to harness this
knowledge, we will
be able to fast-track
the pioneering
vaccine work we’re
doing.”
Matthias Schnell, PhD
Professor of Microbiology and

After decades of research from experts in fields ranging from melanoma
and colon cancer to HIV and rabies, vaccine researchers at Thomas Jefferson
University have established the Jefferson Vaccine Center. This new Center
creates the infrastructure needed to house all of the university’s vaccine
research and clinical efforts, while fostering new collaborations and
innovation.
Under the leadership of Matthias Schnell, PhD, Professor of Microbiology
and Immunology, along with Associate Director Laurence Eisenlohr, VMD,
PhD, Professor of Microbiology and Immunology, the new Center is the
nucleus of immunology research expertise. More than 40 faculty members
are working alongside medical and post-doctoral students to study and
explore new methods for creating vaccines to prevent the spread of such
virulent organisms and diseases as botulism, anthrax, Alzheimer’s, SARS,
and ovarian cancer.
Collaboration and information sharing among vaccine experts is especially
crucial in their journey to develop treatments that prevent the spread of
infectious diseases. Different skill sets and expertise must be combined to
uncover new methodologies for vaccine development. The Center provides

the framework needed to help scientists develop new treatments while
investigating new applications for existing vaccines.
One great example is the work of Robert J. Winn, MD, Medical Director
of Mazzoni Family and Community Medicine, who is conducting a phase
III study of a vaccine that is currently approved to protect women against
cervical cancer and four types of HPV. This clinical trial is studying the
efficacy of the drug in the prevention of anal dysplasia in gay and bisexual
men, a precursor to anal cancer. Should the study prove its effectiveness,
FDA approval will be sought for use of this HPV vaccine in men to prevent
the same strains of HPV as in women.
The Jefferson Vaccine Center also supports the work of renowned
vaccine pioneer, Hilary Koprowski, MD, Professor of Cancer Biology,
who is championing the development of plant-based vaccines. This type
of immunization may someday provide an inexpensive, widely-accessible
means of protection worldwide.
The huge unmet need for new and better vaccines continues to drive
Jefferson scientists in their search for new ways to prevent disease and
improve the course of human health.

Accomplishments
• David Berd, MD, and Michael Mastrangelo, MD,

• World-renowned virologist and immunologist

• Craig Hooper, PhD, Associate Professor of Cancer

Immunology, Director, Jefferson

both professors of Medical Oncology, have

Hilary Koprowski, MD, Professor of Cancer Biology,

Biology, is studying the immunology of rabies

Vaccine Center

developed melanoma vaccines. Dr. Berd’s vaccine,

was honored by his native country, Poland, with

infection, particularly in the brain, while Bernhard

created from a patient’s own tumor cells, has

the renaming of the multimillion dollar Gdansk

Dietzschold, DVM, Professor of Microbiology and

had well-chronicled successes and is currently

Science and Technology Park to the Hilary

Immunology, is working toward devising a new

in clinical testing.

Koprowski Science and Technology Park.

and improved rabies vaccine in wildlife. Both may
reduce deaths, especially in poorer nations.
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Matthias Schnell, PhD, Professor of Microbiology and Immunology and Director of Jefferson’s
newly-established Vaccine Center, reviews the process of separating cells for analysis with fourthyear students Celestine Wanjalla, MD/PhD program, (front) and Elizabeth Faul, PhD program.

Patient Care
“A patient was
too upset after an
appointment to
accurately recall
what had occurred.
The EMR allowed
his family physician
to instantly read the
specialist’s notes
and fully understand
the patient’s
situation.”

Patient Care Information Transformation
Imagine a healthcare system where paper charts no longer exist; where
lab results are available through a secure electronic interface; and the
opportunity for errors is reduced. That time is now, as Jefferson University
Physicians (JUP) implements the first phase of its Electronic Medical
Records (EMR) system.
After a comprehensive system and process redesign, JUP has integrated
EMR into the practices of Family and Community Medicine and the
Department of Otolaryngology. In the spring they went live with TouchWorksTM under the direction of William M. Keane, MD, Executive Sponsor,
and with support from George Valko, MD, physician advocate. Through
this project, desktop computers and other technologies have been placed
in various exam rooms and physician and administrative offices.

George Valko, MD
Vice Chair, Clinical Programs,
Department of Family and
Community Medicine

Accomplishments
• Thomas Jefferson University and the University

• In just over four years, funding for clinical

of Delaware have formed a partnership in the

trials at Thomas Jefferson University has

Medical Scholars, occupational therapy and

increased 37%.

pharmacy programs. Future collaborations are
being considered in nursing, health policy,
population health, rehabilitation sciences, physical
therapy and biomedical engineering.
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• Thomas Jefferson University has increased
the number of endowed professorships to 58.

With a seamless online interface, physicians can have immediate
electronic access to their patients’ health and medication histories as well as
have the ability to record new data. Health information has been scanned into
the system, eliminating more than 65,000 paper charts. The functionality
and efficiency of JUP offices using the technology have significantly
improved and JUP has embraced the EMR as an invaluable tool in providing
a higher level of personalized outpatient care.
George Valko, MD, Vice Chair, Clinical Programs, Family and Community Medicine, is a physician advocate
for Jefferson’s Electronic Medical Records (EMR) system. The system provides “anywhere-anytime” access
to patient records, lab tests and more. With the EMR now live in a number of departments, patients will
experience even higher levels of efficiency through the increased accuracy and information availability the
system provides.

Financials

Operating Expenses

Operating Revenues
• Professional activities
• Grants and contracts
• Hospital support for

35.4%

physician services

12.5%

• Corporate services reimbursement
• Tuition and fees
• State appropriation
• Endowment payout
• Contributions
• Other revenue

20.2%

5.6%
12.5%
1.8%
2.5%
3.1%
6.4%

• Salaries and wages
• Employee benefits
• Financial aid and fellowships
• Insurance
• Utilities
• Bad debt
• Interest
• Depreciation
• Rent
• Supplies and other

53.8%
11.9%
1.3%
3.6%
3.8%
2.6%
1.1%
3.3%
2.2%
16.4%

Financials
Statement of Financial Position

Statement of Activities

As of June 30, 2008
($ in thousands)

As of June 30, 2008
($ in thousands)
Unrestricted

Assets
Cash and short-term investments
Accounts receivable
Assets whose use is limited
Investments
Pledge receivable
Loans receivable
Prepaid pension
Property, plant & equipment
Other assets
Total Assets
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$ 158,319
34,469
49,636
450,252
14,071
30,787
13,981
222,703
15,501
$ 989,719

Liabilities
Accounts payable and accrued expenses
Sponsored program advances
Accrued professional liability
Federal student loan advances
Deferred giving obligations
Deferred revenue
Long-term obligations
Other liabilities
Total Liabilities

$ 68,172
20,179
53,411
18,648
3,961
8,450
186,569
9,529
$ 368,919

Net Assets
Unrestricted
Temporarily restricted
Permanently restricted
Total Net Assets

$ 339,441
158,948
122,411
620,800

Total Liabilities and Net Assets

$ 989,719

Temorarily
Restricted

Permanently
Restricted

Total

How We Received Our Revenues
Professional activities
Grants and contracts – Direct
Hospital support for physician services
Corporate services reimbursement
Tuition and fees
State appropriation
Endowment payout
Net assets released from restriction
Contributions
Other revenue
Total Revenues

$ 212,841
121,193
75,344
33,914
74,988
10,852
7,827
18,326
4,658
38,777
$ 598,720

How We Spent Our Revenues
Salaries and wages
Employee benefits
Financial aid and fellowships
Insurance
Utilities
Bad debt
Interest
Depreciation
Rent
Supplies and other
Subtotal expenses

314,625
69,572
7,810
20,931
22,018
15,067
6,297
19,514
13,019
96,098
$ 584,951

Operating gain

$ 13,769

$

Non-operating items, net

($ 30,556)

($ 13,318)

($

1,638)

($ 45,512)

Decrease in net assets

($ 16,787)

($ 10,727)

($

1,638)

($ 29,152)

Net assets, beginning of year
Net assets, end of year

356,228
$ 339,441

169,675
$ 158,948

124,049
$ 122,411

649,952
$ 620,800

$

7,202
(18,326)
13,715

$

2,591

$ 212,841
121,193
75,344
33,914
74,988
10,852
15,029
0
18,373
38,777
$ 601,311

314,625
69,572
7,810
20,931
22,018
15,067
6,297
19,514
13,019
96,098
$ 584,951
2,591

$ 16,360
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